Genient, a Noida-headquartered clinical genomics and molecular diagnostics company founded in 2017, is entering a decisive new chapter in its evolution — one defined by expanded leadership, sharper clinical focus, and a landmark international distribution partnership that positions it at the forefront of India’s rapidly maturing life sciences ecosystem.
Under the foundational direction of Mr. Anil Kumar, Founder Director — a seasoned technology and consulting leader with prior leadership at HCL Technologies and EY — Genient’s journey represents a deliberate and disciplined transition: from broad-based technology services to a highly specialised role in clinical genomics and molecular diagnostics. This transformation has been driven by India’s surging demand for data-driven, evidence-based diagnostic infrastructure, and by an unwavering awareness of emerging imperatives around data privacy and data integrity in the Indian healthcare context.
Today, Genient operates across infectious diseases, antimicrobial resistance (AMR), oncology, transplant immunology, and clinical genomics research. Its platforms and solutions serve laboratories, hospitals, and academic research institutions — all designed with a singular emphasis on practical, affordable, and scalable deployment within Indian clinical settings.
The appointment of Mr. Brijesh Singh as Chief Executive Officer marks a pivotal inflection point in Genient’s commercial and operational trajectory. Singh brings over two decades of senior leadership across molecular diagnostics — including leadership position as Head of Molecular Diagnostics at Siemens Healthineers encompassing commercial operations, strategic partnerships, and the structured expansion of diagnostics businesses across diverse Indian and global markets.
The convergence of Mr. Kumar’s technology and consulting acumen with Mr. Singh’s diagnostics commercialisation expertise creates a leadership architecture uniquely suited to Genient’s next phase: aligning product development, clinical validation, and operational execution with the real-world requirements of India’s clinical and research user base.
In March 2026, Genient formalised an exclusive distribution agreement with AIT Biotech Pte. Ltd., Singapore — a landmark accord that significantly broadens the depth of genomics instrumentation and assay capabilities available to Indian clinical laboratories.
Founded in 2006 in Singapore by biotechnology entrepreneur, with a vision to build a leading biotechnology company, AIT Biotech has grown to become a premier provider of Molecular Diagnostic (MDx) assays, molecular services, and life science products across Singapore and the Asia-Pacific region. The company holds an ISO 13485-certified laboratory and is both bizSAFE Level 3 and GDPMDS certified — standards that underscore its commitment to quality, safety, and regulatory compliance.
Through this exclusive arrangement, Genient will distribute AIT Biotech’s portfolio of advanced NGS platforms and assays in India, including:
● abSEQ™ Genetic Sequencer — clinical-grade next-generation sequencing platform
● abTRON™ Intelligent Center — integrated informatics and clinical decision support
These platforms are engineered for high-throughput, high-accuracy genomic analysis and align directly with Genient’s core clinical focus areas — infectious disease surveillance, oncology genomics, antimicrobial resistance characterisation, and viral drug resistance profiling.
“The partnership with AIT Biotech is not a conventional distribution arrangement — it is a strategic commitment to bring ISO-certified, clinically validated NGS technology to Indian laboratories that have, for too long, had to work around the absence of such solutions. AIT Biotech’s platforms are proven, precise, and purpose-built for clinical environments. Our exclusive distribution mandate means we can now offer Indian hospitals, research institutions, and diagnostic chains a credible, supported, end-to-end genomics pathway — from sample to clinical insight. This is how we make genomics real for India.”- shared by Brijesh Singh, CEO, Genient
India’s life sciences sector — spanning clinical genomics, genomic data analysis, molecular diagnostics assays, automated instruments, and laboratory consumables — is experiencing an accelerated period of growth, propelled by pressing public health needs: improving disease detection accuracy, enabling drug resistance surveillance, and supporting precision oncology outcomes at scale.
Yet access to advanced genomic tools in India has historically been constrained by cost, supply chain complexity, and a limited number of locally-anchored partners capable of providing both the technology and the technical support required for sustainable deployment. This is precisely the gap that Genient is committed to closing.
Genient’s approach to equitable clinical genomics is grounded in the conviction that world-class genomic diagnostics should not remain the exclusive preserve of large metropolitan hospitals or elite research centres. With the right partnerships, localisation infrastructure, and clinical support architecture, these tools can — and must — reach district-level laboratories, public health institutions, and regional cancer centres across India.
Genient’s trajectory — from technology services to clinical genomics leader — is a story of purposeful alignment between organisational capability and India’s evolving diagnostic needs. With new leadership in place, a robust global partnership ecosystem, and a steadfast commitment to equitable genomics access, the company is well-positioned to participate meaningfully in shaping the next decade of India’s molecular diagnostics landscape.
About Genient Tech Private Limited
Genient is an India-headquartered clinical genomics, molecular diagnostics, and precision genomics company based in Noida, Uttar Pradesh. Operating as a genomics ecosystem architect, Genient maintains global partnerships across Singapore, USA, France, South Korea, Germany, and Turkey. Its clinical focus spans NGS-based genomics, antimicrobial resistance diagnostics, oncology, infectious disease surveillance, and transplant immunology. Genient’s mission is to make clinically actionable genomic diagnostics accessible, affordable, and scalable across India.
About AIT Biotech Pte. Ltd.
Founded in 2006 in Singapore, AIT Biotech Pte. Ltd. is a leading provider of molecular diagnostics, NGS assays, and life science products across Asia. Its portfolio includes the abSEQ™ Genetic Sequencer, abNEX™ assay systems, and abTRON™ Intelligent Center platforms. AIT Biotech holds ISO 13485 laboratory certification and is bizSAFE Level 3 and GDPMDS certified.
Tags:
Genomics
Molecular Diagnostics
Multiplex Respiratory Panels
HIV Whole Genome Sequencing
